Cargando…

Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis

BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuda, Masakazu, Iwanaga, Yoshitaka, Kato, Takao, Izumi, Toshiaki, Inuzuka, Yasutaka, Nakamura, Takashi, Miyaji, Yuki, Kawamura, Takayuki, Ikeguchi, Shigeru, Inoko, Moriaki, Kurita, Takashi, Miyazaki, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975863/
https://www.ncbi.nlm.nih.gov/pubmed/27547432
http://dx.doi.org/10.1136/openhrt-2016-000437
_version_ 1782446787400826880
author Yasuda, Masakazu
Iwanaga, Yoshitaka
Kato, Takao
Izumi, Toshiaki
Inuzuka, Yasutaka
Nakamura, Takashi
Miyaji, Yuki
Kawamura, Takayuki
Ikeguchi, Shigeru
Inoko, Moriaki
Kurita, Takashi
Miyazaki, Shunichi
author_facet Yasuda, Masakazu
Iwanaga, Yoshitaka
Kato, Takao
Izumi, Toshiaki
Inuzuka, Yasutaka
Nakamura, Takashi
Miyaji, Yuki
Kawamura, Takayuki
Ikeguchi, Shigeru
Inoko, Moriaki
Kurita, Takashi
Miyazaki, Shunichi
author_sort Yasuda, Masakazu
collection PubMed
description BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. METHODS: We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. RESULTS: Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal areas, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. CONCLUSIONS: In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior/anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis.
format Online
Article
Text
id pubmed-4975863
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49758632016-08-19 Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis Yasuda, Masakazu Iwanaga, Yoshitaka Kato, Takao Izumi, Toshiaki Inuzuka, Yasutaka Nakamura, Takashi Miyaji, Yuki Kawamura, Takayuki Ikeguchi, Shigeru Inoko, Moriaki Kurita, Takashi Miyazaki, Shunichi Open Heart Heart Failure and Cardiomyopathies BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. METHODS: We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. RESULTS: Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal areas, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. CONCLUSIONS: In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior/anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis. BMJ Publishing Group 2016-08-01 /pmc/articles/PMC4975863/ /pubmed/27547432 http://dx.doi.org/10.1136/openhrt-2016-000437 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Heart Failure and Cardiomyopathies
Yasuda, Masakazu
Iwanaga, Yoshitaka
Kato, Takao
Izumi, Toshiaki
Inuzuka, Yasutaka
Nakamura, Takashi
Miyaji, Yuki
Kawamura, Takayuki
Ikeguchi, Shigeru
Inoko, Moriaki
Kurita, Takashi
Miyazaki, Shunichi
Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title_full Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title_fullStr Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title_full_unstemmed Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title_short Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
title_sort risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac mri in patients with cardiac sarcoidosis
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975863/
https://www.ncbi.nlm.nih.gov/pubmed/27547432
http://dx.doi.org/10.1136/openhrt-2016-000437
work_keys_str_mv AT yasudamasakazu riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT iwanagayoshitaka riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT katotakao riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT izumitoshiaki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT inuzukayasutaka riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT nakamuratakashi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT miyajiyuki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT kawamuratakayuki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT ikeguchishigeru riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT inokomoriaki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT kuritatakashi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis
AT miyazakishunichi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis